Loading...
PLRZ
XNAS
Market cap10mUSD
Nov 20, Last price  
9.31USD
1D
-8.42%
1Q
-9.61%
IPO
-99.63%
Name

Polyrizon Ltd

Chart & performance

D1W1MN
XNAS:PLRZ chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
156.93%
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-3m
L+115.86%
-73,000-711,000-779,000-600,000-1,545,000-3,335,000
CFO
-5m
L+294.77%
-73,000-492,000-1,132,000-537,000-1,147,000-4,528,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Key people

Nir Ben Yosef
Chief Financial Officer · since 2021
Daphna Avital
Chief People Officer · since 2021
Tidhar Turgeman
Chief Technology Officer · since 2024
Eyal Ron
Chief Science Officer · since 2024
Director · since 2021
Director · since 2025
Tomer Izraeli
Chief Executive Officer, Director · since 2020
Independent Director · since 2024
Independent Director · since 2024
Omer Srugo
Independent Director · since 2024
Yehonatan Vinokur
Independent Director · since 2024
IPO date
Oct 29, 2024
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT